ResMed Company Profile (NYSE:RMD)

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

ResMed declared a quarterly dividend on Wednesday, August 2nd. Shareholders of record on Thursday, August 17th will be paid a dividend of $0.35 per share on Thursday, September 21st. This represents a $1.40 annualized dividend and a yield of 1.81%. The ex-dividend date of this dividend is Tuesday, August 15th. This is a positive change from ResMed's previous quarterly dividend of $0.33. View ResMed's Dividend History.

ResMed Inc. (NYSE:RMD) announced its earnings results on Tuesday, August, 1st. The company reported $0.77 EPS for the quarter, beating analysts' consensus estimates of $0.75 by $0.02. The company had revenue of $556.69 million for the quarter, compared to the consensus estimate of $557.68 million. ResMed had a net margin of 16.56% and a return on equity of 21.99%. The company's quarterly revenue was up 7.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.74 earnings per share. View ResMed's Earnings History.

ResMed is scheduled to release their next quarterly earnings announcement on Monday, October, 23rd 2017. View Earnings Estimates for ResMed.

10 analysts have issued twelve-month target prices for ResMed's shares. Their predictions range from $56.00 to $72.00. On average, they anticipate ResMed's share price to reach $66.00 in the next twelve months. View Analyst Ratings for ResMed.

Here are some recent quotes from research analysts about ResMed stock:

• 1. According to Zacks Investment Research, "ResMed exited fourth-quarter fiscal 2017 on a promising note with earnings and revenues beating the Zacks Consensus Estimate. The company achieved high single-digit global revenue growth this quarter, led by sales of sleep devices, respiratory care devices, mask systems and software solutions. Also, Brightree has acted as a significant contributor to the company’s operating results through 2017. Notably, over the last three months, ResMed is trading significantly above the broader industry. We believe, ResMed’s product launches and strategies to gain traction in the SDB market are expected to boost its performance further in the near term. Its recent published favorable study result on COPD is expected to open up new scope in this line. Yet, challenges like competitive bidding and reimbursement issues continue to plague the stock. Rising operating expenses and a weak operating margin are other major woes for ResMed." (8/3/2017)
• 2. Needham & Company LLC analysts commented, "RMD’s revenue missed consensus but its EPS beat consensus in F4Q17. Organic revenue growth increased to 8% in F4Q17 from 6% in F3Q17 as RMD saw higher flow generator growth partly offset by a slowdown in masks due to supply constraints in the first two months of the quarter. While RMD’s gross margin was slightly lower than expected, it was more than offset by lower than expected SG&A and R&D allowing RMD’s operating margin to beat our estimate. We maintain our Underperform rating since we believe that RMD’s longer-run revenue growth potential is similar to its large-cap peers (mid-single digit revenue growth and 8-10% EPS growth —possibly generous since we note that RMD’s EPS growth has averaged just 4% for the past three years) while its multiple is at a premium (CY17E P/E of 26.5x vs. large-cap med tech peers at 24.3x)." (8/2/2017)

Some companies that are related to ResMed include Agilent Technologies (A), Waters (WAT), Hologic (HOLX), Varian Medical Systems (VAR), PerkinElmer (PKI), ABIOMED (ABMD), Bruker Corporation (BRKR), Alere (ALR), Quidel Corporation (QDEL), Mazor Robotics (MZOR), Accelerate Diagnostics (AXDX), Natus Medical (BABY), ABAXIS (ABAX), Luminex Corporation (LMNX), LeMaitre Vascular (LMAT), Pacific Biosciences of California (PACB), GenMark Diagnostics (GNMK) and Accuray Incorporated (ARAY).

ResMed's management team includes the folowing people:

• Rob Douglas, President, Chief Operating Officer
• Michael Farrell, Chief Executive Officer, Director
• Brett A. Sandercock, Chief Financial Officer
• Jim Hollingshead Ph.D., President - Americas
• Anne Reiser, President – Europe & Asia Pacific
• David Pendarvis, Chief Administrative Officer, Global General Counsel, Company Secretary
• Agnes Lee, Senior Director - Investor Relations
• Peter C. Farrell Ph.D., Non-Executive Chairman of the Board
• Ronald R. Taylor, Lead Independent Director
• Carol J. Burt, Independent Director

ResMed's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (10.01%), Vanguard Group Inc. (8.38%), Capital World Investors (7.09%), FMR LLC (3.90%), Baillie Gifford & Co. (3.42%) and State Street Corp (3.24%). Company insiders that own ResMed stock include Anne Reiser, Brett Sandercock, Christopher G Roberts, David Pendarvis, Donald Darkin, Franz Kozich, Gary W Pace, James Hollingshead, John P Wareham, Jr Gregor K Emmert, Michael J Farrell, Peter C Farrell, Richard Sulpizio, Robert Andrew Douglas, Ronald R Taylor and Warren Russell Hawkins. View Institutional Ownership Trends for ResMed.

ResMed's stock was sold by a variety of institutional investors in the last quarter, including WINTON GROUP Ltd, TIAA CREF Investment Management LLC, Capital World Investors, Russell Investments Group Ltd., Schroder Investment Management Group, JPMorgan Chase & Co., Baillie Gifford & Co. and Bank of Montreal Can. Company insiders that have sold ResMed stock in the last year include Brett Sandercock, Christopher G Roberts, David Pendarvis, Gary W Pace, James Hollingshead, John P Wareham, Michael J Farrell, Peter C Farrell and Richard Sulpizio. View Insider Buying and Selling for ResMed.

ResMed's stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Koch Industries Inc., BlackRock Inc., Vanguard Group Inc., First Trust Advisors LP, Janus Henderson Group PLC, Quantitative Investment Management LLC and Northern Trust Corp. Company insiders that have bought ResMed stock in the last two years include Franz Kozich, Jr Gregor K Emmert, Ronald R Taylor and Warren Russell Hawkins. View Insider Buying and Selling for ResMed.

Shares of ResMed can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ResMed stock can currently be purchased for approximately $77.38.